A peek into COVAX machine; The curious case of the prequalification of Remdesivir

By Priti Patnaik

Geneva Health Files "(...) Our story this week, takes a close look inside Gavi’s COVAX Facility - its governance structures and contracts with countries. Thorny issues of liability provisions and cost-sharing, especially with respect to low-income countries continue to be hashed out. Read on. In addition, we also try to understand why Remdesivir was prequalified a day before WHO announced the results of its Solidarity Trial, declaring its ineffectiveness in treating COVID-19. This was brought to our attention by one of our sources." (Photo: Jernej Furman/flickr; CC BY 2.0)

genevahealthfiles.substack.com